Gilead Sciences (GILD) 105.96 $GILD
IBD 50 Stocks Setting Up, Including These 5 Medicals
at Investor's Business Daily - Fri Sep 19, 6:36PM CDT
Recent volatility in the stock market, including an outlook shift to uptrend under pressure and back to a confirmed uptrend, may have rattled investors' nerves. But it's also helped set up new potential entries as some leading stocks slipped into buy...
VIVUS and Auxilium Announce Stendra Label Expansion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 5:25PM CDT
VIVUS, Inc. (VVUS) and Auxilium Pharmaceuticals, Inc. (AUXL) announced that the FDA has approved Stendra's supplemental new drug application.
Most active Nasdaq-traded stocks
AP - Fri Sep 19, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Final Glance: Biotechnology companies
AP - Fri Sep 19, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Bristol-Myers' (BMY) Yervoy Label Expanded in Canada - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 4:40PM CDT
Bristol-Myers' (BMY) Yervoy gained Canadian approval for treating adults newly diagnosed with advanced melanoma.
Spectrum Pharmaceuticals Out-Licenses Products in China - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 4:15PM CDT
Spectrum Pharmaceuticals (SPPI) announced that it has out-licensed two approved products and a candidate to CASI Pharmaceuticals.
Bayer to Shed MaterialScience Business, Shares Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 4:10PM CDT
Bayer (BAYRY) announced its intention to shed its MaterialScience business and focus fully on its HealthCare and CropScience segments.
Eli Lilly's Trulicity Approved by FDA for Type II Diabetes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 3:50PM CDT
Eli Lilly and Company (LLY) received good news when the FDA approved its new injectable diabetes treatment, Trulicity, for adults suffering from type II diabetes.
Is Merck KGaA on Track with its "Fit for 2018" Program? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 1:50PM CDT
Merck KGaA (MKGAF) remains on track for its "Fit for 2018" program and discusses its plans regarding the immunology, oncology and immuno-oncology pipeline.
Midday Glance: Biotechnology companies
AP - Fri Sep 19, 12:33PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Dividend Aristocrats: Time to Buy AbbVie Inc Stock?
George Budwell, The Motley Fool - Motley Fool - Fri Sep 19, 11:32AM CDT
Dividend stocks are a powerful force within a well-balanced portfolio because they can dramatically increase the rate of compounding interest through dividend reinvestment plans. Not all dividend stocks are great investment vehicles, however. For...
Gilead's Zydelig Approved In EU; Imbruvica In Wings
at Investor's Business Daily - Fri Sep 19, 11:17AM CDT
The European Commission (EC) approved Gilead Sciences' (GILD) drug Zydelig for two blood cancers on Friday, sending Gilead stock up as much as 1.9%, though shares were flat in midday trading in the stock market today. The EC approved the drug for...
5 Things Gilead Sciences, Inc. Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Fri Sep 19, 10:30AM CDT
Gilead Sciences presented at the Morgan Stanley Healthcare Conference last week. Rather than the standard presentation of a slide deck, the conference is more of a Q&A, which produces off-the-cuff responses that can be more enlightening for...
Early Glance: Biotechnology companies
AP - Fri Sep 19, 9:16AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Stock Market News for September 19, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 9:10AM CDT
Benchmarks settled in the green on Thursday a day after Fed’s pledge to keep short-term interest rates near zero for a “considerable time”
VIVUS Inc. (VVUS) Rises: Stock Adds 12.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 8:32AM CDT
VIVUS Inc. (VVUS) was a big mover last session, as the company saw its shares rise more than 12% on the day.
Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent
PR Newswire - Fri Sep 19, 7:15AM CDT
BioTech News Coverage: Progress made as biotech companies release latest developments, patents and results of studies and trials. Companies in focus are: GenSpera Inc. (OTC: GNSZ), Eli Lilly and Company (NYSE: LLY), Gilead Sciences Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA)
European Commission Grants Marketing Authorization for Gilead's Zydelig(R) (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
Business Wire - Fri Sep 19, 5:23AM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the European Commission has granted marketing authorization for Zydelig(R) (idelalisib), 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers - chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). For the treatment of CLL, Zydelig has been approved for use in combination with rituximab for patients who have received at least one prior therapy; or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy. For the treatment of FL, Zydelig has been approved as a monotherapy in patients who are refractory to two prior lines of treatment. Zydelig inhibits PI3K delta, a protein that is overexpressed in many B-cell malignancies and plays a role in the viability, proliferation and migration of these cancer cells.
Sanofi & MyoKardia Ink Deal to Develop Cardiomyopathies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:35PM CDT
Sanofi (SNY) announced that it has entered into an agreement with MyoKardia, Inc. to discover and develop targeted therapeutics for cardiomyopathies.
Bayer/Orion Progress with Prostate Cancer Drug ODM-201 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:15PM CDT
Bayer (BAYRY) and Orion Corp. announced that they have started enrolling patients for a phase III study on ODM-201.
IBD 50 Stocks Setting Up, Including These 5 Medicals
at Investor's Business Daily - Fri Sep 19, 6:36PM CDT
Recent volatility in the stock market, including an outlook shift to uptrend under pressure and back to a confirmed uptrend, may have rattled investors' nerves. But it's also helped set up new potential entries as some leading stocks slipped into buy...
VIVUS and Auxilium Announce Stendra Label Expansion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 5:25PM CDT
VIVUS, Inc. (VVUS) and Auxilium Pharmaceuticals, Inc. (AUXL) announced that the FDA has approved Stendra's supplemental new drug application.
Most active Nasdaq-traded stocks
AP - Fri Sep 19, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Final Glance: Biotechnology companies
AP - Fri Sep 19, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Bristol-Myers' (BMY) Yervoy Label Expanded in Canada - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 4:40PM CDT
Bristol-Myers' (BMY) Yervoy gained Canadian approval for treating adults newly diagnosed with advanced melanoma.
Spectrum Pharmaceuticals Out-Licenses Products in China - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 4:15PM CDT
Spectrum Pharmaceuticals (SPPI) announced that it has out-licensed two approved products and a candidate to CASI Pharmaceuticals.
Bayer to Shed MaterialScience Business, Shares Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 4:10PM CDT
Bayer (BAYRY) announced its intention to shed its MaterialScience business and focus fully on its HealthCare and CropScience segments.
Eli Lilly's Trulicity Approved by FDA for Type II Diabetes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 3:50PM CDT
Eli Lilly and Company (LLY) received good news when the FDA approved its new injectable diabetes treatment, Trulicity, for adults suffering from type II diabetes.
Is Merck KGaA on Track with its "Fit for 2018" Program? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 1:50PM CDT
Merck KGaA (MKGAF) remains on track for its "Fit for 2018" program and discusses its plans regarding the immunology, oncology and immuno-oncology pipeline.
Midday Glance: Biotechnology companies
AP - Fri Sep 19, 12:33PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Dividend Aristocrats: Time to Buy AbbVie Inc Stock?
George Budwell, The Motley Fool - Motley Fool - Fri Sep 19, 11:32AM CDT
Dividend stocks are a powerful force within a well-balanced portfolio because they can dramatically increase the rate of compounding interest through dividend reinvestment plans. Not all dividend stocks are great investment vehicles, however. For...
Gilead's Zydelig Approved In EU; Imbruvica In Wings
at Investor's Business Daily - Fri Sep 19, 11:17AM CDT
The European Commission (EC) approved Gilead Sciences' (GILD) drug Zydelig for two blood cancers on Friday, sending Gilead stock up as much as 1.9%, though shares were flat in midday trading in the stock market today. The EC approved the drug for...
5 Things Gilead Sciences, Inc. Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Fri Sep 19, 10:30AM CDT
Gilead Sciences presented at the Morgan Stanley Healthcare Conference last week. Rather than the standard presentation of a slide deck, the conference is more of a Q&A, which produces off-the-cuff responses that can be more enlightening for...
Early Glance: Biotechnology companies
AP - Fri Sep 19, 9:16AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Stock Market News for September 19, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 9:10AM CDT
Benchmarks settled in the green on Thursday a day after Fed’s pledge to keep short-term interest rates near zero for a “considerable time”
VIVUS Inc. (VVUS) Rises: Stock Adds 12.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 8:32AM CDT
VIVUS Inc. (VVUS) was a big mover last session, as the company saw its shares rise more than 12% on the day.
Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent
PR Newswire - Fri Sep 19, 7:15AM CDT
BioTech News Coverage: Progress made as biotech companies release latest developments, patents and results of studies and trials. Companies in focus are: GenSpera Inc. (OTC: GNSZ), Eli Lilly and Company (NYSE: LLY), Gilead Sciences Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA)
European Commission Grants Marketing Authorization for Gilead's Zydelig(R) (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
Business Wire - Fri Sep 19, 5:23AM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the European Commission has granted marketing authorization for Zydelig(R) (idelalisib), 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers - chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). For the treatment of CLL, Zydelig has been approved for use in combination with rituximab for patients who have received at least one prior therapy; or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy. For the treatment of FL, Zydelig has been approved as a monotherapy in patients who are refractory to two prior lines of treatment. Zydelig inhibits PI3K delta, a protein that is overexpressed in many B-cell malignancies and plays a role in the viability, proliferation and migration of these cancer cells.
Sanofi & MyoKardia Ink Deal to Develop Cardiomyopathies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:35PM CDT
Sanofi (SNY) announced that it has entered into an agreement with MyoKardia, Inc. to discover and develop targeted therapeutics for cardiomyopathies.
Bayer/Orion Progress with Prostate Cancer Drug ODM-201 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:15PM CDT
Bayer (BAYRY) and Orion Corp. announced that they have started enrolling patients for a phase III study on ODM-201.
